Status:
WITHDRAWN
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
Lead Sponsor:
Abbott
Collaborating Sponsors:
Genentech, Inc.
Conditions:
B-cell Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2b, open-label, multicenter, global study assessing the safety and efficacy of ABT-263 in subjects with B-cell CLL who have failed at least one prior fludarabine-containing regimen.
Eligibility Criteria
Inclusion
- \>= 18 yrs of age, have B-cell CLL, failed at least 1 prior fludarabine-containing regimen.
- Refractory to 1 fludarabine-containing regimen is defined as failure to achieve at least PR to the last fludarabine-containing regimen received, or disease progression while receiving the last fludarabine-containing regimen, or disease progression in responders (i.e., achieved a PR or CR) within 6 mos of the last cycle of the last fludarabine-containing regimen received (e.g., fludarabine monotherapy, FR, or FC) or in responders (i.e., achieved a PR or CR ) within 24 mos of the last cycle of FCR.
- Intolerant to fludarabine is defined as discontinuation of therapy within 2 cycles due to side effects/toxicity from the last fludarabine-containing regimen.
- ECOG score of \<=1.
- Adequate coagulation, renal, \& hepatic function at Screening as follows:
- Serum creatinine \<= 2.0 mg/dL or calculated creatinine clearance \>= 50 mL/min;
- AST \& ALT \<= 3.0 x ULN;
- Bilirubin \<= 1.5 x ULN.
- Gilbert's Syndrome may have a Bilirubin \> 1.5 x ULN; aPTT, PT, not to exceed 1.2 x ULN.
- Adequate bone marrow (BM) independent of any growth factor support (with the exception of subjects with BM heavily infiltrated with underlying disease \[80% or more\] who may use growth factor support to achieve adequate BM) at Screening as follows:
- ANC \>= 1000/µL;
- Platelets \>= 75,000/mm3 (entry platelet count must be independent of transfusion within 14 days of Screening);
- Hemoglobin \>= 9.0 g/dL.
- History of autologous BM transplant must be \> 6 mos post transplant (prior to the 1st dose of study drug) \& have adequate BM independent of any growth factor support (with the exception of subjects with BM that is heavily infiltrated with underlying disease \[80% or more\] who may use growth factor support to achieve adequate BM) at Screening as follows:
- ANC \>= 1500/µL;
- Platelets \>= 125,000/mm3;
- Hemoglobin \>= 10.0 g/dL.
- Female subjects must be surgically sterile, postmenopausal (at least 1 year), or have negative results on a pregnancy test.
- All female subjects not surgically sterile or postmenopausal (at least 1 year) \& non-vasectomized male subjects must practice birth control.
Exclusion
- History/clinically suspicious for cancer-related CNS disease.
- Undergone allogeneic stem cell transplant.
- Undergone autologous stem cell transplant w/i 6 mos prior to 1st dose.
- History/predisposing condition of bleeding or currently exhibits signs of bleeding.
- Recent history of non-chemotherapy induced thrombocytopenic associated bleeding w/i 6 mos prior to 1st dose.
- Active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
- Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions w/i 1 yr prior to 1st dose.
- Currently receiving/requires anticoagulation therapy or any drugs or herbal supplements that affect platelet function, with the exception of low-dose anticoagulation medications used to maintain the patency of a central IV catheter.
- Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease.
- Positive for HIV, Hepatitis B, or Hepatitis C.
- Previous or current malignancies w/i the last 3 yrs:
- except adequately treated in situ carcinoma of the cervix uteri;
- basal or squamous cell carcinoma;
- in situ carcinoma of the bladder;
- or previous malignancy confined and surgically resected with curative intent.
- Has Prolymphocytic leukemia or Richter's transformation to an aggressive B-cell malignancy.
- Exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to uncontrolled systemic infection or diagnosis of fever and neutropenia w/i 1 week prior to study drug.
- Prior exposure to ABT-263.
- Received antibody therapy w/i 30 days prior to 1st dose.
- Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, or any investigational therapy w/i 14 days prior to the 1st dose, or has not recovered to \<Gr2 clinically significant AE(s) /toxicity(s) of the previous therapy.
- Received steroid therapy for anti-neoplastic intent, w/i 7 days prior to the 1st dose with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids.
- Received aspirin w/i 7 days prior to the 1st dose.
- Consumed grapefruit or grapefruit products w/i 3 days prior to 1st dose.
- Females pregnant or breast-feeding.
Key Trial Info
Start Date :
March 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00918450
Start Date
March 1 2010
Last Update
February 26 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.